-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Net, May 17 News Following the first review of doxorubicin hydrochloride liposome injection, CSPC has reviewed two more injections.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
Meropenem is a carbapenem antibiotic, which is mainly used for adult and children infections caused by single or multiple bacteria that are sensitive to meropenem.
According to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
According to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
At present, meropenem for injection has been evaluated by 3 companies , including Haibin Pharmaceutical, Hanhui Pharmaceutical, and CSPC.
Meropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
Meropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
The brand pattern of meropenem in China's public medical institutions in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol hydrochloride is a mucolytic agent developed by Boehringer Ingelheim.
Ambroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Ambroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Ambroxol hydrochloride injection is the fourth batch of collected varieties, and the lowest winning bid is RMB 0.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
Up to now, CSPC has passed/deemedly passed the consistency evaluation of 51 varieties (80 product specifications).
Medical Net, May 17 News Following the first review of doxorubicin hydrochloride liposome injection, CSPC has reviewed two more injections.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
Meropenem is a carbapenem antibiotic, which is mainly used for adult and children infections caused by single or multiple bacteria that are sensitive to meropenem.
According to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
According to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
At present, meropenem for injection has been evaluated by 3 companies , including Haibin Pharmaceutical, Hanhui Pharmaceutical, and CSPC.
Meropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
Meropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
The brand pattern of meropenem in China's public medical institutions in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol hydrochloride is a mucolytic agent developed by Boehringer Ingelheim.
Ambroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Ambroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Ambroxol hydrochloride injection is the fourth batch of collected varieties, and the lowest winning bid is RMB 0.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
Up to now, CSPC has passed/deemedly passed the consistency evaluation of 51 varieties (80 product specifications).
Medical Net, May 17 News Following the first review of doxorubicin hydrochloride liposome injection, CSPC has reviewed two more injections.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
On May 14, the official website of NMPA showed that CSPC’s meropenem for injection and ambroxol hydrochloride injection passed the consistency evaluation, and meropenem for injection was the third one to pass the evaluation.
In 2020, China's public medical institutions will sell meropenem on the terminal.
The amount exceeds 5 billion yuan.
At present, CSPC has already reviewed 51 products.
Meropenem is a carbapenem antibiotic, which is mainly used for adult and children infections caused by single or multiple bacteria that are sensitive to meropenem.
According to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
Children's and Children 's Hospital Hospital HospitalAccording to Meinenet data, in 2020, the sales of terminal meropenem in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 5 billion yuan, and Sumitomo of Japan had a 40.
86% market share.
At present, meropenem for injection has been evaluated by 3 companies , including Haibin Pharmaceutical, Hanhui Pharmaceutical, and CSPC.
Meropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
Enterprise business enterpriseMeropenem for injection has not yet been included in centralized procurement, and Haibin Pharmaceutical and CSPC have the market share leading other domestic companies.
The brand pattern of meropenem in China's public medical institutions in 2020
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Ambroxol hydrochloride is a mucolytic agent developed by Boehringer Ingelheim.
Ambroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Disease disease disease baby infant babyAmbroxol hydrochloride injection is mainly used for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion ; postoperative pulmonary complications Preventive treatment of disease; treatment of infant respiratory distress syndrome in premature infants and neonates .
Ambroxol hydrochloride injection is the fourth batch of collected varieties, and the lowest winning bid is RMB 0.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
23 per tube (2ml: 15mg) of Yunnan Longhai Pharmaceutical.
According to data from Meinenet, in 2020, the sales of terminal ambroxol injections in public medical institutions in China will exceed 3.
6 billion yuan, and Boehringer Ingelheim will occupy 25.
01% of the market share.
Up to now, CSPC has passed/deemedly passed the consistency evaluation of 51 varieties (80 product specifications).
